The myristate moiety and amino terminus of vaccinia virus L1 constitute a bipartite functional region needed for entry

Journal of Virology

Volumn 86, Issue 10, 2012, Pages 5437-5451

  Foo, Chwan Hong ^a   Whitbeck, J Charles ^a   Ponce de León, Manuel ^a   Saw, Wan Ting ^a   Cohen, Gary H ^a   Eisenberg, Roselyn J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ENTRY FUSION COMPLEX PROTEIN; MUTANT PROTEIN; MYRISTIC ACID; UNCLASSIFIED DRUG; VACCINIA VIRUS L1 PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; MYRISTYLATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VACCINIA VIRUS; VIRION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INFECTIVITY; VIRUS MUTANT; WILD TYPE;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; CELL LINE; HUMANS; MOLECULAR SEQUENCE DATA; MYRISTIC ACID; SEQUENCE ALIGNMENT; VACCINIA; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION;

VACCINIA VIRUS;

EID: 84861318525     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06703-11     Document Type: Article

References (86)

1. Abramoff MD, Magalhaes PJ, Ram SJ. 2004. Image processing with ImageJ. Biophotonics Int. 11:36-42.
2. Aldaz-Carroll L, et al. 2005. Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Virology 341:59 -71.
3. Ames JB, et al. 1997. Molecular mechanics of calcium-myristoyl switches. Nature 389:198 -202.
4. Ames JB, Tanaka T, Stryer L, Ikura M. 1996. Portrait of a myristoyl switch protein. Curr. Opin. Struct. Biol. 6:432- 438.
5. Bengali Z, Townsley AC, Moss B. 2009. Vaccinia virus strain differences in cell attachment and entry. Virology 389:132-140.
6. Bisht H, Brown E, Moss B. 2010. Kinetics and intracellular location of intramolecular disulfide bond formation mediated by the cytoplasmic redox system encoded by vaccinia virus. Virology 398:187-193.
7. Bisht H, Weisberg AS, Moss B. 2008. Vaccinia virus L1 protein is required for cell entry and membrane fusion. J. Virol. 82:8687- 8694.
8. Blouch RE, Byrd CM, Hruby DE. 2005. Importance of disulphide bonds for vaccinia virus L1R protein function. Virol. J. 2:91.
9. Boutin JA. 1997. Myristoylation. Cell Signal. 9:15-35.
10. Brown E, Senkevich TG, Moss B. 2006. Vaccinia virus F9 virion membrane protein is required for entry but not virus assembly, in contrast to the related L1 protein. J. Virol. 80:9455-9464.
11. Bruss V, Hagelstein J, Gerhardt E, Galle PR. 1996. Myristylation of the large surface protein is required for hepatitis B virus in vitro infectivity. Virology 218:396 -399.
12. Capul AA, et al. 2007. Arenavirus Z-glycoprotein association requires Z myristoylation but not functional RING or late domains. J. Virol. 81: 9451-9460.
13. Chang SJ, Chang YX, Izmailyan R, Tang YL, Chang W. 2010. Vaccinia virus A25 and A26 proteins are fusion suppressors for mature virions and determine strain-specific virus entry pathways into HeLa, CHO-K1, and L cells. J. Virol. 84:8422- 8432.
14. Chiu WL, Lin CL, Yang MH, Tzou DL, Chang W. 2007. Vaccinia virus 4c (A26L) protein on intracellular mature virus binds to the extracellular cellular matrix laminin. J. Virol. 81:2149 -2157.
15. Chung CS, Hsiao JC, Chang YS, Chang W. 1998. A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate. J. Virol. 72: 1577-1585.
16. Cole C, Barber JD, Barton GJ. 2008. The Jpred 3 secondary structure prediction server. Nucleic Acids Res. 36:W197-W201.
17. Condit RC, Moussatche N, Traktman P. 2006. In a nutshell: structure and assembly of the vaccinia virion. Adv. Virus Res. 66:31-124.
18. Dill KA, et al. 1995. Principles of protein folding-a perspective from simple exact models. Protein Sci. 4:561- 602.
19. Eisenberg RJ, et al. 1987. Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2. Microb. Pathog. 3:423- 435.
20. Evan GI, Lewis GK, Ramsay G, Bishop JM. 1985. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol. Cell. Biol. 5:3610 -3616.
21. Farazi TA, Waksman G, Gordon JI. 2001. The biology and enzymology of protein N-myristoylation. J. Biol. Chem. 276:39501-39504.
22. Fogg C, et al. 2004. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J. Virol. 78:10230 -10237.
23. Foo CH, et al. 2009. Vaccinia virus L1 binds to cell surfaces and blocks virus entry independently of glycosaminoglycans. Virology 385:368 -382.
24. Franke CA, Reynolds PL, Hruby DE. 1989. Fatty acid acylation of vaccinia virus proteins. J. Virol. 63:4285- 4291.
25. Franke CA, Wilson EM, Hruby DE. 1990. Use of a cell-free system to identify the vaccinia virus L1R gene product as the major late myristylated virion protein M25. J. Virol. 64:5988 -5996.
26. Gottlinger HG, Sodroski JG, Haseltine WA. 1989. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U. S. A. 86:5781-5785.
27. Gripon P, Le Seyec J, Rumin S, Guguen-Guillouzo C. 1995. Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity. Virology 213:292-299.
28. Henderson DA. 1987. Principles and lessons from the smallpox eradication programme. Bull. World Health Organ. 65:535-546.
29. Heraud JM, et al. 2006. Subunit recombinant vaccine protects against monkeypox. J. Immunol. 177:2552-2564.
30. Hooper JW, Custer DM, Schmaljohn CS, Schmaljohn AL. 2000. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology 266:329 -339.
31. Hooper JW, et al. 2004. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol. 78:4433- 4443.
32. Hsiao JC, Chung CS, Chang W. 1999. Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. J. Virol. 73:8750-8761.
33. Ichihashi Y. 1996. Extracellular enveloped vaccinia virus escapes neutralization. Virology 217:478-485.
34. Ichihashi Y, Oie M. 1996. Neutralizing epitope on penetration protein of vaccinia virus. Virology 220:491- 494.
35. Ichihashi Y, Takahashi T, Oie M. 1994. Identification of a vaccinia virus penetration protein. Virology 202:834-843.
36. Izmailyan RA, Huang CY, Mohammad S, Isaacs SN, Chang W. 2006. The envelope G3L protein is essential for entry of vaccinia virus into host cells. J. Virol. 80:8402- 8410.
37. Kennedy RB, Ovsyannikova I, Poland GA. 2009. Smallpox vaccines for biodefense. Vaccine 27(Suppl. 4):D73-D79.
38. Knipe DM, et al (ed). 2007. Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
39. Kochan G, Escors D, Gonzalez JM, Casasnovas JM, Esteban M. 2007. Membrane cell fusion activity of the vaccinia virus A17-A27 protein complex. Cell Microbiol. 10:149 -164.
40. Koshizuka T, Kawaguchi Y, Nozawa N, Mori I, Nishiyama Y. 2007. Herpes simplex virus protein UL11 but not UL51 is associated with lipid rafts. Virus Genes 35:571-575.
41. Kyte J, Doolittle RF. 1982. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157:105-132.
42. Lin CL, Chung CS, Heine HG, Chang W. 2000. Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo. J. Virol. 74:3353-3365.
43. Macrae DR, Bruss V, Ganem D. 1991. Myristylation of a duck hepatitis B virus envelope protein is essential for infectivity but not for virus assembly. Virology 181:359 -363.
44. Matsubara M, Nakatsu T, Kato H, Taniguchi H. 2004. Crystal structure of a myristoylated CAP-23/NAP-22 N-terminal domain complexed with Ca2 /calmodulin. EMBO J. 23:712-718.
45. Mercer J, et al. 2010. Vaccinia virus strains use distinct forms of macropinocytosis for host-cell entry. Proc. Natl. Acad. Sci. U. S. A. 107:9346 -9351.
46. Moss B. 2001. Poxviridae: the viruses and their replication, p 2849-2883. In Knipe DM, et al (ed), Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
47. Nelson GE, Sisler JR, Chandran D, Moss B. 2008. Vaccinia virus entry/ fusion complex subunit A28 is a target of neutralizing and protective antibodies. Virology 380:394-401.
48. Nelson GE, Wagenaar TR, Moss B. 2008. A conserved sequence within the H2 subunit of the vaccinia virus entry/fusion complex is important for interaction with the A28 subunit and infectivity. J. Virol. 82:6244-6250.
49. Nichols RJ, Stanitsa E, Unger B, Traktman P. 2008. The vaccinia virus gene I2L encodes a membrane protein with an essential role in virion entry. J. Virol. 82:10247-10261.
50. Ojeda S, Domi A, Moss B. 2006. Vaccinia virus G9 protein is an essential component of the poxvirus entry-fusion complex. J. Virol. 80:9822-9830.
51. Ojeda S, Senkevich TG, Moss B. 2006. Entry of vaccinia virus and cell-cell fusion require a highly conserved cysteine-rich membrane protein encoded by the A16L gene. J. Virol. 80:51- 61.
52. Ravanello MP, Franke CA, Hruby DE. 1993. An NH2-terminal peptide from the vaccinia virus L1R protein directs the myristylation and virion envelope localization of a heterologous fusion protein. J. Biol. Chem. 268: 7585-7593.
53. Ravanello MP, Hruby DE. 1994. Characterization of the vaccinia virus L1R myristylprotein as a component of the intracellular virion envelope. J. Gen. Virol. 75:1479 -1483.
54. Ravanello MP, Hruby DE. 1994. Conditional lethal expression of the vaccinia virus L1R myristylated protein reveals a role in virion assembly. J. Virol. 68:6401- 6410.
55. Resh MD. 1999. Fatty acylation of proteins: new insights into membrane targeting of myristoylated and palmitoylated proteins. Biochim. Biophys. Acta 1451:1-16.
56. Resh MD. 2006. Trafficking and signaling by fatty-acylated and prenylated proteins. Nat. Chem. Biol. 2:584 -590.
57. Rux AH, et al. 1998. Functional region IV of glycoprotein D from herpes simplex virus modulates glycoprotein binding to the herpesvirus entry mediator. J. Virol. 72:7091-7098.
58. Sandgren KJ, et al. 2010. A differential role for macropinocytosis in mediating entry of the two forms of vaccinia virus into dendritic cells. PLoS Pathog. 6:e1000866.
59. Satheshkumar PS, Moss B. 2009. Characterization of a newly identified 35-amino-acid component of the vaccinia virus entry/fusion complex conserved in all chordopoxviruses. J. Virol. 83:12822-12832.
60. Schrempf S, Froeschke M, Giroglou T, von Laer D, Dobberstein B. 2007. Signal peptide requirements for lymphocytic choriomeningitis virus glycoprotein C maturation and virus infectivity. J. Virol. 81:12515-12524.
61. Schultz AM, Rein A. 1989. Unmyristylated Moloney murine leukemia virus Pr65gag is excluded from virus assembly and maturation events. J. Virol. 63:2370 -2373.
62. Senkevich TG, Moss B. 2005. Vaccinia virus H2 protein is an essential component of a complex involved in virus entry and cell-cell fusion. J. Virol. 79:4744-4754.
63. Senkevich TG, Ojeda S, Townsley A, Nelson GE, Moss B. 2005. Poxvirus multiprotein entry-fusion complex. Proc. Natl. Acad. Sci. U. S. A. 102: 18572-18577.
64. Senkevich TG, Ward BM, Moss B. 2004. Vaccinia virus entry into cells is dependent on a virion surface protein encoded by the A28L gene. J. Virol. 78:2357-2366.
65. Senkevich TG, Weisberg AS, Moss B. 2000. Vaccinia virus E10R protein is associated with the membranes of intracellular mature virions and has a role in morphogenesis. Virology 278:244 -252.
66. Senkevich TG, White CL, Koonin EV, Moss B. 2002. Complete pathway for protein disulfide bond formation encoded by poxviruses. Proc. Natl. Acad. Sci. U. S. A. 99:6667- 6672.
67. Senkevich TG, White CL, Koonin EV, Moss B. 2000. A viral member of the ERV1/ALR protein family participates in a cytoplasmic pathway of disulfide bond formation. Proc. Natl. Acad. Sci. U. S. A. 97:12068 -12073.
68. Su HP, et al. 2005. The 1.51-Angstrom structure of the poxvirus L1 protein, a target of potent neutralizing antibodies. Proc. Natl. Acad. Sci. U. S. A. 102:4240-4245.
69. Su HP, Golden JW, Gittis AG, Hooper JW, Garboczi DN. 2007. Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. Virology 368:331-341.
70. Takasaki A, Hayashi N, Matsubara M, Yamauchi E, Taniguchi H. 1999. Identification of the calmodulin-binding domain of neuron-specific protein kinase C substrate protein CAP-22/NAP-22. Direct involvement of protein myristoylation in calmodulin-target protein interaction. J. Biol. Chem. 274:11848 -11853.
71. Taniguchi H. 1999. Protein myristoylation in protein-lipid and proteinprotein interactions. Biophys. Chem. 82:129 -137.
72. Tessier DC, Thomas DY, Khouri HE, Laliberte F, Vernet T. 1991. Enhanced secretion from insect cells of a foreign protein fused to the honeybee melittin signal peptide. Gene 98:177-183.
73. Thaa B, et al. 2009. Myristoylation of the arterivirus E protein: the fatty acid modification is not essential for membrane association but contributes significantly to virus infectivity. J. Gen. Virol. 90:2704 -2712.
74. Townsley AC, Senkevich TG, Moss B. 2005. The product of the vaccinia virus L5R gene is a fourth membrane protein encoded by all poxviruses that is required for cell entry and cell-cell fusion. J. Virol. 79:10988 -10998.
75. Townsley AC, Senkevich TG, Moss B. 2005. Vaccinia virus A21 virion membrane protein is required for cell entry and fusion. J. Virol. 79:9458- 9469.
76. Turner PC, et al. 2007. Vaccinia virus temperature-sensitive mutants in the A28 gene produce non-infectious virions that bind to cells but are defective in entry. Virology 366:62-72.
77. Utsumi T, et al. 2004. Vertical-scanning mutagenesis of amino acids in a model N-myristoylation motif reveals the major amino-terminal sequence requirements for protein N-myristoylation. Eur. J. Biochem. 271: 863-874.
78. Valentine KG, Mesleh MF, Opella SJ, Ikura M, Ames JB. 2003. Structure, topology, and dynamics of myristoylated recoverin bound to phospholipid bilayers. Biochemistry 42:6333- 6340.
79. Weiergraber OH, Senin II, Philippov PP, Granzin J, Koch KW. 2003. Impact of N-terminal myristoylation on the Ca2 -dependent conformational transition in recoverin. J. Biol. Chem. 278:22972-22979.
80. Welker R, Harris M, Cardel B, Krausslich HG. 1998. Virion incorporation of human immunodeficiency virus type 1 Nef is mediated by a bipartite membrane-targeting signal: analysis of its role in enhancement of viral infectivity. J. Virol. 72:8833- 8840.
81. Whitbeck JC, Foo CH, Ponce de Leon M, Eisenberg RJ, Cohen GH. 2009. Vaccinia virus exhibits cell-type-dependent entry characteristics. Virology 385:383-391.
82. White CL, Weisberg AS, Moss B. 2000. A glutaredoxin, encoded by the G4L gene of vaccinia virus, is essential for virion morphogenesis. J. Virol. 74:9175-9183.
83. Wolfe CL, Ojeda S, Moss B. 2012. Transcriptional repression and RNA silencing act synergistically to demonstrate the function of the eleventh component of the vaccinia virus entry-fusion complex. J. Virol. 86:293- 301.
84. Wolffe EJ, Vijaya S, Moss B. 1995. A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Virology 211:53- 63.
85. Xiao Y, et al. 2007. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine 25:1214 -1224.
86. York J, Romanowski V, Lu M, Nunberg JH. 2004. The signal peptide of the Junin arenavirus envelope glycoprotein is myristoylated and forms an essential subunit of the mature G1-G2 complex. J. Virol. 78:10783-10792.